TIMELINE-50
MRP: 3,500
Packaging: 50MG
Pack Type: injection
Composition:
Tigecycline USP 50 mg
Indication:
To treat certain serious infections including community acquired pneumonia (a lung infection that developed in a person who was not in the hospital), skin infections
Description:
Tigecycline USP 50 mg is a broad-spectrum glycylcycline antibiotic, derived from the tetracycline class. It is used for the treatment of complicated infections caused by multidrug-resistant (MDR) bacteria, including MRSA, VRE (Vancomycin-Resistant Enterococci), and ESBL-producing Gram-negative organisms.
Tigecycline works by inhibiting bacterial protein synthesis by binding to the 30S ribosomal subunit, making it effective against both aerobic and anaerobic bacteria, Gram-positive and Gram-negative strains.
It is indicated for:
Complicated intra-abdominal infections (cIAI)
Complicated skin and soft tissue infections (cSSTI)
Community-acquired bacterial pneumonia (CAP)
Infections caused by resistant organisms when other treatments are unsuitable
Note: Tigecycline is for intravenous (IV) use only.
Tags:
- Potent activity against MDR pathogens including MRSA, VRE, and ESBL
- Useful when standard antibiotics fail
- Broad-spectrum coverage including anaerobes
- No renal dose adjustment required
- Well tolerated in most patients under supervision
Usage Information
Dosage
Initial Dose: 100 mg IV loading dose Maintenance Dose: 50 mg IV every 12 hours Route: Intravenous infusion over 30–60 minutes Treatment Duration: Typically 5–14 days, depending on infection severity and response
Side Effects
Common: Nausea, vomiting Diarrhea Injection site irritation Elevated liver enzymes Serious (rare): Pancreatitis Anaphylaxis or hypersensitivity Clostridium difficile–associated diarrhea Increased mortality in severe infections (use with caution)
Contraindications
Hypersensitivity to Tigecycline or tetracyclines Pregnancy and breastfeeding Use with caution in severe hepatic impairment Avoid in pediatric patients unless absolutely necessary